Down-regulated FOS, TGFβR2 and up-regulated TPX2 among all drug-treated CML cases as well as significantly up-regulated LAPTM4B, PIEZO2, ANGPT1, CFH, CD109 and HLTF molecule in TKI-resistant cases were validated in 23 Imatinib-treated CML cases. Here, LAPTM4B is linked to chronic myelogenous leukemia, BCR-ABL1 positive.